Indivior, INC.
Healthcare company
Based in VA
🤖
AI Overview
With $1.6M in lobbying spend across 27 quarterly filings, Indivior, INC. is a significant lobbying presence. They deploy 13 individual lobbyists
$1.6M
Total Lobbying Spend
27
Quarterly Filings
1
Lobbying Firms Used
13
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $270K |
| 2019 | $160K |
| 2020 | $240K |
| 2021 | $240K |
| 2022 | $240K |
| 2023 | $240K |
| 2024 | $160K |
Lobbying Firms
WILLIAMS AND JENSEN, PLLC
What They Lobby For
- S. 916, Protecting Patient Access to emergency Medications Act of 2017; H.R.5205 Ensuring Patient Access to substance Use Disorder Treatments Act of 2018; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; H.R. 1492 Medical Controlled Substances Transportation Act of 2017; Implementation of the CARA Act; H.R. 1628 American Health Care Act of 2017.
- Issues related to tax.
- S. 916, Protecting Patient Access to emergency Medications Act of 2017; H.R.5205 Ensuring Patient Access to substance Use Disorder Treatments Act of 2018; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; H.R. 1492 Medical Controlled Substances Transportation Act of 2017; Implementation of the CARA Act.
- S. 916, Protecting Patient Access to emergency Medications Act of 2017; H.R.5205 Ensuring Patient Access to substance Use Disorder Treatments Act of 2018; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; H.R. 1492 Medical Controlled Substances Transportation Act of 2017; Implementation of the CARA Act. H.R. 6, Support for Patients and Communities Act.
- Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment; Implementation of CARA Act. H.R. 6, Support for Patients and Communities Act.
- Issues related to tax. Tax credits and tax issues related to the pharmaceutical industry.
- Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment; Implementation of CARA Act. H.R. 6, Support for Patients and Communities Act. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
- Issues related to Drug Enforcement Agency (DEC) implementation of S. 916; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; Implementation of CARA Act. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
- Opioid Addiction Treatment policies. Appropriation issues related to DEA. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
- Issues related to Drug Enforcement Agency (DEC) implementation of S. 916; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; Implementation of CARA Act. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 4712 Fairness in Orphan Drug Exclusivity Act. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.